Objectives: Call on people to treat the causes of physical diseases is to take into account the causes of psychological factors as well as external causes. Materials and Methods: The analysis was conducted by combining the classical medical books of Tibetan medicine, as well as the traditional culture and living habits of Tibetan people, with modern research results. Results: Many of the theories mentioned in Tibetan medicine related to mind-body medicine have been confirmed by modern research. Mental and physical treatment related to psychosomatic diseases should be administered simultaneously. First, when a person is healthy, he should cultivate his mind to build a solid psychological defense against diseases. Developing both the mind and body contributes to creating a stable physical protection barrier against diseases. When a person is ill, he should realign his mind and help his body adjust and promote its early recovery with the help of medications. Conclusions: Treating related psychosomatic diseases should treat the mind and body simultaneously. And the mind and body should be cultivated before diseases to reinforce the psychological and physical defense against diseases.
{"title":"The psychosomatic thought of tibetan medicine and its treatment methods","authors":"Zijuan Zhang, Xin Li, Yasong Cheng, Amatti Jorigori, Dongzhu Renqing, Liwen Pan, Meng Mao, Xiao-Qiao Ren, Huizhen Zhao","doi":"10.4103/2311-8571.373598","DOIUrl":"https://doi.org/10.4103/2311-8571.373598","url":null,"abstract":"Objectives: Call on people to treat the causes of physical diseases is to take into account the causes of psychological factors as well as external causes. Materials and Methods: The analysis was conducted by combining the classical medical books of Tibetan medicine, as well as the traditional culture and living habits of Tibetan people, with modern research results. Results: Many of the theories mentioned in Tibetan medicine related to mind-body medicine have been confirmed by modern research. Mental and physical treatment related to psychosomatic diseases should be administered simultaneously. First, when a person is healthy, he should cultivate his mind to build a solid psychological defense against diseases. Developing both the mind and body contributes to creating a stable physical protection barrier against diseases. When a person is ill, he should realign his mind and help his body adjust and promote its early recovery with the help of medications. Conclusions: Treating related psychosomatic diseases should treat the mind and body simultaneously. And the mind and body should be cultivated before diseases to reinforce the psychological and physical defense against diseases.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"330 - 337"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45603556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.382025
Hong-Sheng Lin, Ying Zhang, Chu-Chu Zhang, Su-ying Liu, Jie Liu, Peilun Yang
Objective: This article discusses the following aspects, including the history of traditional Chinese medicine (TCM) in the treatment of lung cancer, the breakthrough in the theory of TCM in treatment of lung cancer, clinical study of TCM in treating lung cancer, microscientific interpretation of TCM treatment for lung cancer and the prospect of TCM in treating lung cancer. Materials and Methods: In this paper, through a systematic search, combing traditional Chinese medicine prevention and treatment of lung cancer ancient books and modern literature. Results: A series of large sample and multi-centered clinical studies have proved that TCM comprehensive treatment significantly improves the clinical efficacy for lung cancer. “TCM treatment system for non-small cell lung cancer” based on staged and standardized integration of TCM and Western medicine has been well developed and popularized in practice. Furthermore, in virtue of the international cooperation platform established by the National Cancer Institute of the United States, the scientific connotation of TCM in the prevention and treatment of lung cancer is systematically and deeply studied, thereby promoting the research and development of new Chinese drugs for lung cancer. Conclusions: Nowadays, TCM has realized a landmark breakthrough in treating lung cancer, bringing benefits to all lung cancer patients.
{"title":"Lung cancer treatment in traditional chinese medicine: History, current status, and development","authors":"Hong-Sheng Lin, Ying Zhang, Chu-Chu Zhang, Su-ying Liu, Jie Liu, Peilun Yang","doi":"10.4103/2311-8571.382025","DOIUrl":"https://doi.org/10.4103/2311-8571.382025","url":null,"abstract":"Objective: This article discusses the following aspects, including the history of traditional Chinese medicine (TCM) in the treatment of lung cancer, the breakthrough in the theory of TCM in treatment of lung cancer, clinical study of TCM in treating lung cancer, microscientific interpretation of TCM treatment for lung cancer and the prospect of TCM in treating lung cancer. Materials and Methods: In this paper, through a systematic search, combing traditional Chinese medicine prevention and treatment of lung cancer ancient books and modern literature. Results: A series of large sample and multi-centered clinical studies have proved that TCM comprehensive treatment significantly improves the clinical efficacy for lung cancer. “TCM treatment system for non-small cell lung cancer” based on staged and standardized integration of TCM and Western medicine has been well developed and popularized in practice. Furthermore, in virtue of the international cooperation platform established by the National Cancer Institute of the United States, the scientific connotation of TCM in the prevention and treatment of lung cancer is systematically and deeply studied, thereby promoting the research and development of new Chinese drugs for lung cancer. Conclusions: Nowadays, TCM has realized a landmark breakthrough in treating lung cancer, bringing benefits to all lung cancer patients.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"297 - 306"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45237473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.355009
Meng-Meng Wang, Xinghui Zhang, Jun-Yan Wang, Jing Xua, Ming-zhu Chen, Shuyue Wang, M. Jia, Zhiping Shen, Ling Zhang, Y. Gong, Jian Gong
The objective of this study was to systematically evaluate the efficacy and safety of Huachansu capsules in the treatment of esophageal cancer. We searched all relevant Chinese and English documents in the Cochrane Library Clinical Controlled Trials, PubMed, EMBASE, CNKI, and VIP databases, from the time the databases were established to December 2020. The studies were selected according to the inclusion and exclusion criteria, and their quality was evaluated. We used RevMan 5.4 to conduct the meta-analysis of measurement indicators and intervention measures. Six randomized controlled trials comprising 526 patients with esophageal cancer were included in the study. Compared with radiotherapy and chemotherapy alone, oral Huachansu capsules combined with radiotherapy and chemotherapy improved the clinical efficacy (risk ratio [RR] = 1.35, 95% confidence interval [CI], 1.17–1.55, P < 0.0001), quality of life (weighted mean difference [MD] = 10.01, 95% CI [3.39–16.64], P = 0.003), and immune level (CD3+: MD = 4.99, 95% CI [3.70–6.29], P < 0.0001; CD4+: MD = 6.49, 95% CI [5.55–7.42], P < 0.0001; CD5+: MD = 0.20, 95% CI [0.11–0.28], P < 0.0001), and reduced toxic and side effects (reductions in white blood cell count: RR = 0.63, 95% CI [0.44–0.90], P = 0.01; Reductions in blood platelet: RR = 0.70, 95% CI [0.52–0.94], P = 0.02; Gastrointestinal reaction: RR = 0.73, 95% CI [0.59–0.89], P = 0.002). However, the number of included studies was small, and conclusions still need to be further verified using larger samples and high-quality randomized, double-blind controlled trials.
{"title":"Efficacy and safety of huachansu capsules for the treatment of esophageal cancer: A systematic review and meta-analysis","authors":"Meng-Meng Wang, Xinghui Zhang, Jun-Yan Wang, Jing Xua, Ming-zhu Chen, Shuyue Wang, M. Jia, Zhiping Shen, Ling Zhang, Y. Gong, Jian Gong","doi":"10.4103/2311-8571.355009","DOIUrl":"https://doi.org/10.4103/2311-8571.355009","url":null,"abstract":"The objective of this study was to systematically evaluate the efficacy and safety of Huachansu capsules in the treatment of esophageal cancer. We searched all relevant Chinese and English documents in the Cochrane Library Clinical Controlled Trials, PubMed, EMBASE, CNKI, and VIP databases, from the time the databases were established to December 2020. The studies were selected according to the inclusion and exclusion criteria, and their quality was evaluated. We used RevMan 5.4 to conduct the meta-analysis of measurement indicators and intervention measures. Six randomized controlled trials comprising 526 patients with esophageal cancer were included in the study. Compared with radiotherapy and chemotherapy alone, oral Huachansu capsules combined with radiotherapy and chemotherapy improved the clinical efficacy (risk ratio [RR] = 1.35, 95% confidence interval [CI], 1.17–1.55, P < 0.0001), quality of life (weighted mean difference [MD] = 10.01, 95% CI [3.39–16.64], P = 0.003), and immune level (CD3+: MD = 4.99, 95% CI [3.70–6.29], P < 0.0001; CD4+: MD = 6.49, 95% CI [5.55–7.42], P < 0.0001; CD5+: MD = 0.20, 95% CI [0.11–0.28], P < 0.0001), and reduced toxic and side effects (reductions in white blood cell count: RR = 0.63, 95% CI [0.44–0.90], P = 0.01; Reductions in blood platelet: RR = 0.70, 95% CI [0.52–0.94], P = 0.02; Gastrointestinal reaction: RR = 0.73, 95% CI [0.59–0.89], P = 0.002). However, the number of included studies was small, and conclusions still need to be further verified using larger samples and high-quality randomized, double-blind controlled trials.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"270 - 277"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41348931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.382112
Baojin Han, Ya-jie Liu, Jia-Yue Jin, Hong-Kun Xu, Wenze Zhang, Si-Meng Ren, Xin Wang, Jie Liu
Patients with lung cancer may experience various symptoms as the disease progresses, which may reduce the benefits of cancer treatment, reduce treatment compliance, delay cancer treatment, reduce the quality of life (QoL), and impact survival. This review discusses comprehensive symptom assessment and management, which are crucial for high-quality lung cancer treatment. Traditional Chinese medicine (TCM) is important in relieving cancer-related symptoms in patients with lung cancer. Including patient-reported outcomes (PROs) in clinical trials and practice can provide a better assessment of symptom burden and the effectiveness of symptom management. Patient-centered care with TCM in lung cancer patients may include six steps: Symptom screening, etiology investigation, comprehensive assessment, integrative management, reassessment, and regular symptom follow-up monitoring. PRO measures can be used to evaluate symptom intensity, the degree to which symptoms interfere with activities of daily living, and the QoL. Clearly defined and reliable PRO measures can enhance patient satisfaction and improve symptom control. Quantitative PRO measures developed from the TCM perspective should be considered one of the important outcome measurements in TCM care. A multidisciplinary collaborative symptom management model, including TCM and conventional therapy, will be the future goal for treating patients with lung cancer.
{"title":"Symptom assessment and management in patients with lung cancer undergoing conventional or traditional chinese medicine care","authors":"Baojin Han, Ya-jie Liu, Jia-Yue Jin, Hong-Kun Xu, Wenze Zhang, Si-Meng Ren, Xin Wang, Jie Liu","doi":"10.4103/2311-8571.382112","DOIUrl":"https://doi.org/10.4103/2311-8571.382112","url":null,"abstract":"Patients with lung cancer may experience various symptoms as the disease progresses, which may reduce the benefits of cancer treatment, reduce treatment compliance, delay cancer treatment, reduce the quality of life (QoL), and impact survival. This review discusses comprehensive symptom assessment and management, which are crucial for high-quality lung cancer treatment. Traditional Chinese medicine (TCM) is important in relieving cancer-related symptoms in patients with lung cancer. Including patient-reported outcomes (PROs) in clinical trials and practice can provide a better assessment of symptom burden and the effectiveness of symptom management. Patient-centered care with TCM in lung cancer patients may include six steps: Symptom screening, etiology investigation, comprehensive assessment, integrative management, reassessment, and regular symptom follow-up monitoring. PRO measures can be used to evaluate symptom intensity, the degree to which symptoms interfere with activities of daily living, and the QoL. Clearly defined and reliable PRO measures can enhance patient satisfaction and improve symptom control. Quantitative PRO measures developed from the TCM perspective should be considered one of the important outcome measurements in TCM care. A multidisciplinary collaborative symptom management model, including TCM and conventional therapy, will be the future goal for treating patients with lung cancer.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"235 - 242"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44610799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.382023
Dao-rui Li, W. Hou, B. Hua, Pei-tong Zhang, Lu Xiong, Hao Liu, Qi-Yuan Mao, Hong-Sheng Lin, B. Piao
Objective: The objective of this study was to examine the effect of the postsurgical administration of Shenyi capsules on the outcome and overall survival of patients with nonsmall cell lung cancer (NSCLC). Materials and Methods: This was a multicenter, randomized, placebo-controlled, double-blind clinical trial. Patients with stages I–IIIA NSCLC were randomized to Shenyi or placebo groups (treatment duration: 6 months) and followed up for 10 years. One-year, 2-year, 5-year, and 10-year survival rates and survival times were calculated. Symptoms, quality of life, traditional Chinese medicine (TCM) syndrome, and recurrence were evaluated. Results: A total of 361 patients (treatment group, n = 185; placebo group, n = 176) were randomized and followed up for 10 years. The two groups had similar baseline demographic and clinical characteristics. Among all 361 patients, the treatment group had significantly longer median survival (31 months, respectively) than the placebo group (22.3 months, P < 0.01). In stage II or III patients, recurrence and metastasis rates in the treatment group were lower than those in the placebo group (P < 0.05). The treatment group also had significantly longer 1-year and 2-year survival rates based on the full analysis set and per-protocol set; however, there was no statistically significant difference in the 5-year and 10-year survival rates (P < 0.01 for all comparisons). Multivariate analysis of variance showed that the interaction between stage and age had a significant impact on overall survival (P < 0.05). Compared with the placebo group, the treatment group showed a significant decrease in TCM syndrome (P < 0.01) and a significant increase in the Karnofsky Performance Score (P < 0.01) and body weight (P < 0.05). Conclusions: Adjunctive therapy with Shenyi capsules significantly prolonged the 1-year and 2-year survival rates after surgery and improved the quality of life. Moreover, none of the patients experienced severe adverse effects. These results suggest that Shenyi capsules may have clinical applications in treating patients with NSCLC.
{"title":"Shenyi capsule prolongs postoperative survival of patients with nonsmall cell lung cancer: A multicenter, randomized, controlled trial","authors":"Dao-rui Li, W. Hou, B. Hua, Pei-tong Zhang, Lu Xiong, Hao Liu, Qi-Yuan Mao, Hong-Sheng Lin, B. Piao","doi":"10.4103/2311-8571.382023","DOIUrl":"https://doi.org/10.4103/2311-8571.382023","url":null,"abstract":"Objective: The objective of this study was to examine the effect of the postsurgical administration of Shenyi capsules on the outcome and overall survival of patients with nonsmall cell lung cancer (NSCLC). Materials and Methods: This was a multicenter, randomized, placebo-controlled, double-blind clinical trial. Patients with stages I–IIIA NSCLC were randomized to Shenyi or placebo groups (treatment duration: 6 months) and followed up for 10 years. One-year, 2-year, 5-year, and 10-year survival rates and survival times were calculated. Symptoms, quality of life, traditional Chinese medicine (TCM) syndrome, and recurrence were evaluated. Results: A total of 361 patients (treatment group, n = 185; placebo group, n = 176) were randomized and followed up for 10 years. The two groups had similar baseline demographic and clinical characteristics. Among all 361 patients, the treatment group had significantly longer median survival (31 months, respectively) than the placebo group (22.3 months, P < 0.01). In stage II or III patients, recurrence and metastasis rates in the treatment group were lower than those in the placebo group (P < 0.05). The treatment group also had significantly longer 1-year and 2-year survival rates based on the full analysis set and per-protocol set; however, there was no statistically significant difference in the 5-year and 10-year survival rates (P < 0.01 for all comparisons). Multivariate analysis of variance showed that the interaction between stage and age had a significant impact on overall survival (P < 0.05). Compared with the placebo group, the treatment group showed a significant decrease in TCM syndrome (P < 0.01) and a significant increase in the Karnofsky Performance Score (P < 0.01) and body weight (P < 0.05). Conclusions: Adjunctive therapy with Shenyi capsules significantly prolonged the 1-year and 2-year survival rates after surgery and improved the quality of life. Moreover, none of the patients experienced severe adverse effects. These results suggest that Shenyi capsules may have clinical applications in treating patients with NSCLC.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"314 - 321"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43740398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.351512
S. Sachdeva, Jaspreet Kaur, Sanjana Mehta, Renu Saharan, Parminder Nain
The incidence of nephrolithiasis, commonly known as kidney stone, is increasing worldwide with significant health and economic burden. Approximately 2 million people every year in India are affected by kidney stones. It affects all ages, genders, and races, but between the ages of 20 and 49 years, it affects most frequently in men than women. Different types of stones include calcium stones, cysteine stones, struvite or magnesium ammonium phosphate stones, uric acid stones, and drug-induced stones. This review article provides information about general pathophysiology, epidemiology, clinical presentation, and pharmacological treatment, which includes ayurvedic and herbal medicines for nephrolithiasis. Further understanding of the pathophysiological link between nephrolithiasis and systemic disorders is necessary for the development of new therapeutic options.
{"title":"Formulation of ayurvedic medicines and extracts of medicinal plants as an alternative therapeutic treatment option for nephrolithiasis","authors":"S. Sachdeva, Jaspreet Kaur, Sanjana Mehta, Renu Saharan, Parminder Nain","doi":"10.4103/2311-8571.351512","DOIUrl":"https://doi.org/10.4103/2311-8571.351512","url":null,"abstract":"The incidence of nephrolithiasis, commonly known as kidney stone, is increasing worldwide with significant health and economic burden. Approximately 2 million people every year in India are affected by kidney stones. It affects all ages, genders, and races, but between the ages of 20 and 49 years, it affects most frequently in men than women. Different types of stones include calcium stones, cysteine stones, struvite or magnesium ammonium phosphate stones, uric acid stones, and drug-induced stones. This review article provides information about general pathophysiology, epidemiology, clinical presentation, and pharmacological treatment, which includes ayurvedic and herbal medicines for nephrolithiasis. Further understanding of the pathophysiological link between nephrolithiasis and systemic disorders is necessary for the development of new therapeutic options.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"278 - 283"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46397134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.343650
Ling-Ling Chu, Bin Li, Jia Wu, Ling Jiang, Xudong Zhou, Wen-bing Sheng, Cai-yun Peng, Salman Zafar, Ping-an Liu, Wei Wang
Rodgersia is a traditional Chinese medicine that contains a variety of chemical constituents, including flavonoids, terpenoids, phenylpropanoids, gallic acid derivatives, steroids, volatile oils, and tannins, with anti-inflammatory, antioxidant, antitumor, antibacterial, antivirus, hepatoprotective, and other properties. In this paper, the main chemical constituents and pharmacological effects of Rodgersia are summarized. On this basis, the quality markers of this genus were predicted based on chemical composition, traditional medicinal properties, traditional efficacy, and measurable components. This review provides the basis for in-depth research, utilization, and quality control of Rodgersia.
{"title":"Research progress on Rodgersia and predictive analysis on its quality markers","authors":"Ling-Ling Chu, Bin Li, Jia Wu, Ling Jiang, Xudong Zhou, Wen-bing Sheng, Cai-yun Peng, Salman Zafar, Ping-an Liu, Wei Wang","doi":"10.4103/2311-8571.343650","DOIUrl":"https://doi.org/10.4103/2311-8571.343650","url":null,"abstract":"Rodgersia is a traditional Chinese medicine that contains a variety of chemical constituents, including flavonoids, terpenoids, phenylpropanoids, gallic acid derivatives, steroids, volatile oils, and tannins, with anti-inflammatory, antioxidant, antitumor, antibacterial, antivirus, hepatoprotective, and other properties. In this paper, the main chemical constituents and pharmacological effects of Rodgersia are summarized. On this basis, the quality markers of this genus were predicted based on chemical composition, traditional medicinal properties, traditional efficacy, and measurable components. This review provides the basis for in-depth research, utilization, and quality control of Rodgersia.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"243 - 257"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43962135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.369650
Su Fu, Shaojia Qin, W. Rausch
Objective: This study aimed to reveal the antitumor effects of Chinese herbal formulae and the underlying mechanisms in treating colorectal cancer, with a focus on developing traditional Chinese medicine (TCM) as a supplement and alternative therapeutic method for cancers. Materials and Methods: Human colon cancer SW480 cells were treated with three Chinese herbal formulae, Bu Zhong Yi Qi Decoction, Fuzi Lizhong Decoction, and Pulsatilla Decoction at different concentrations (50–600 μg/mL) for 24, 36, and 48 h, respectively. Cell viability was determined using the resazurin reduction assay, and cell survival rate was evaluated using a colony formation assay. After treatment with different concentrations (50–600 μg/mL) of these three formulae for 48 h, the effects of the Chinese herbal formulae on cell apoptosis were investigated using Hoechst/propidium iodide (PI) staining. The positive PI-stained cells were investigated using an EnSpire multilabel plate reader and the positive Hoechst-stained cells were observed under a fluorescence microscope for morphological changes. Results: Bu Zhong Yi Qi Decoction, Fuzi Lizhong Decoction, and Pulsatilla Decoction inhibited SW480 cell proliferation in a dose-and time-dependent manner and induced cell apoptosis. Conclusion: Chinese herbal formulae with a special prescription form of TCM with antitumor effects bring a new perspective in line with the principles of TCM in cancer treatment.
{"title":"Chinese herb formulae inhibit the proliferation of human colon cancer SW480 cells by inducing cell apoptosis","authors":"Su Fu, Shaojia Qin, W. Rausch","doi":"10.4103/2311-8571.369650","DOIUrl":"https://doi.org/10.4103/2311-8571.369650","url":null,"abstract":"Objective: This study aimed to reveal the antitumor effects of Chinese herbal formulae and the underlying mechanisms in treating colorectal cancer, with a focus on developing traditional Chinese medicine (TCM) as a supplement and alternative therapeutic method for cancers. Materials and Methods: Human colon cancer SW480 cells were treated with three Chinese herbal formulae, Bu Zhong Yi Qi Decoction, Fuzi Lizhong Decoction, and Pulsatilla Decoction at different concentrations (50–600 μg/mL) for 24, 36, and 48 h, respectively. Cell viability was determined using the resazurin reduction assay, and cell survival rate was evaluated using a colony formation assay. After treatment with different concentrations (50–600 μg/mL) of these three formulae for 48 h, the effects of the Chinese herbal formulae on cell apoptosis were investigated using Hoechst/propidium iodide (PI) staining. The positive PI-stained cells were investigated using an EnSpire multilabel plate reader and the positive Hoechst-stained cells were observed under a fluorescence microscope for morphological changes. Results: Bu Zhong Yi Qi Decoction, Fuzi Lizhong Decoction, and Pulsatilla Decoction inhibited SW480 cell proliferation in a dose-and time-dependent manner and induced cell apoptosis. Conclusion: Chinese herbal formulae with a special prescription form of TCM with antitumor effects bring a new perspective in line with the principles of TCM in cancer treatment.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"348 - 354"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45649323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-01DOI: 10.4103/2311-8571.351793
Jiangxue Zhou, Huizhen Zhao, Ai-ping Chen, Zijuan Zhang, Jingzhou Li, Ling Zuo, Yajun Cheng, D. Deng, Xue-Li Li, Xiao-yun Ma, Da Man, Ming Zheng, Jing Chen, Bo Wen, Juan Wang
Background: Hypertension affects over 1 billion people globally and is the top risk factor of cardiovascular morbidity and mortality. Wuweijiangyasan (WWJYS), as an empirical prescription, has stable depressurization effects. This study investigated the chemical composition and pharmacodynamic effects of WWJYS in regulating the blood pressure (BP), emotion, and blood lipid of spontaneous hypertensive rats, and further explored the depressurization mechanism of WWJYS. Materials and Methods: This study used network pharmacology to identify the origins and predict targets of WWJYS, and artificial intelligence-based molecular docking is used to further predict targets and mechanisms. The chemical constituents of WWJYS were analyzed and identified by ultra high-performance liquid chromatography–mass spectrometry (MS)/MS. Results: In the WWJYS group, the systolic BP level significantly was decreased, and the HR was stable. The irritability became stable after the 5-week treatment compared with the model group (P < 0.05). Rats' rotation tolerance time increased after 2-weeks stabilization. Compared with the model group, angiotensin-converting enzyme 2 protein and mRNA of the WWJYS group increased significantly (P < 0.05). Network pharmacology collected 64 compounds and identified 22 potential targets of WWJYS for antihypertensive activity. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that WWJYS might regulate smooth muscle cells, affect inflammatory response and improve endothelial function through multiple pathways. The molecular docking study further supported that the target proteins have good combinations with the main active components of WWJYS. Conclusions: The data indicated that WWJYS had significant depressurization, analgesic, and sedative, as well as lipid-lowering effects, and the depressurization mechanism of WWJYS may function in multiple signal pathways, especially in improving blood vessel function and intervening inflammation.
背景：高血压影响着全球超过10亿人，是心血管疾病发病率和死亡率的最高风险因素。五味降压散（WWJYS）作为一种经验方，具有稳定的降压效果。本研究考察了WWJYS的化学成分及其对自发性高血压大鼠血压、情绪和血脂的调节作用，并进一步探讨了WWJYS的降压机制。材料与方法：本研究采用网络药理学方法确定WWJYS的起源和预测靶标，并采用基于人工智能的分子对接方法进一步预测靶标和机制。采用超高效液相色谱-质谱（MS）/MS对WWJYS的化学成分进行了分析鉴定。结果：WWJYS组收缩压明显下降，HR稳定。治疗5周后应激反应较模型组稳定（P＜0.05），2周后大鼠旋转耐受时间增加。与模型组相比，WWJYS组的血管紧张素转换酶2蛋白和mRNA显著增加（P<0.05）。网络药理学收集了64个化合物，鉴定了22个WWJYS降压活性的潜在靶点。Gene Ontology和Kyoto Encyclopedia of Genes and Genomes富集分析表明，WWJYS可能通过多种途径调节平滑肌细胞、影响炎症反应和改善内皮功能。分子对接研究进一步支持了靶蛋白与WWJYS的主要活性成分具有良好的组合。结论：WWJYS具有显著的降压、镇痛、镇静和降脂作用，其降压机制可能通过多种信号通路发挥作用，尤其是在改善血管功能和干预炎症方面。
{"title":"Mechanism of wuweijiangyasan in the treatment of spontaneous hypertension based on network pharmacology","authors":"Jiangxue Zhou, Huizhen Zhao, Ai-ping Chen, Zijuan Zhang, Jingzhou Li, Ling Zuo, Yajun Cheng, D. Deng, Xue-Li Li, Xiao-yun Ma, Da Man, Ming Zheng, Jing Chen, Bo Wen, Juan Wang","doi":"10.4103/2311-8571.351793","DOIUrl":"https://doi.org/10.4103/2311-8571.351793","url":null,"abstract":"Background: Hypertension affects over 1 billion people globally and is the top risk factor of cardiovascular morbidity and mortality. Wuweijiangyasan (WWJYS), as an empirical prescription, has stable depressurization effects. This study investigated the chemical composition and pharmacodynamic effects of WWJYS in regulating the blood pressure (BP), emotion, and blood lipid of spontaneous hypertensive rats, and further explored the depressurization mechanism of WWJYS. Materials and Methods: This study used network pharmacology to identify the origins and predict targets of WWJYS, and artificial intelligence-based molecular docking is used to further predict targets and mechanisms. The chemical constituents of WWJYS were analyzed and identified by ultra high-performance liquid chromatography–mass spectrometry (MS)/MS. Results: In the WWJYS group, the systolic BP level significantly was decreased, and the HR was stable. The irritability became stable after the 5-week treatment compared with the model group (P < 0.05). Rats' rotation tolerance time increased after 2-weeks stabilization. Compared with the model group, angiotensin-converting enzyme 2 protein and mRNA of the WWJYS group increased significantly (P < 0.05). Network pharmacology collected 64 compounds and identified 22 potential targets of WWJYS for antihypertensive activity. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that WWJYS might regulate smooth muscle cells, affect inflammatory response and improve endothelial function through multiple pathways. The molecular docking study further supported that the target proteins have good combinations with the main active components of WWJYS. Conclusions: The data indicated that WWJYS had significant depressurization, analgesic, and sedative, as well as lipid-lowering effects, and the depressurization mechanism of WWJYS may function in multiple signal pathways, especially in improving blood vessel function and intervening inflammation.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"355 - 368"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45003622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Transdermal drug delivery plays a significant part in the drug delivery system when compared to other routes of drug administration. The function of the stratum corneum (SC) is a barrier. Recently, numerous methods have been thrived to improve the perforation of drugs across the skin. The most effective method is to use enhancers since these agents enhance skin permeability. Natural penetration enhancers like essential oils demonstrate higher enhancement activity and are more widely accepted than synthetic penetration enhancers. High potential in the expansion and interaction with the SC intercellular lipids has led to an increasing interest in these oils as penetration enhancers. This article gives an overview of a few essential oils, including their mode of action and important parameters for permeation improvement. The present work can provide essential oils as alternative enhancers, and this could be useful in transdermal administration.
{"title":"Potential of essential oils as alternative permeation enhancers for transdermal delivery","authors":"Jayshree Mahanty, Sofi Rasheed, Sudhir Kumar, Harjeet Singh, Alok K. Sharma","doi":"10.4103/2311-8571.351508","DOIUrl":"https://doi.org/10.4103/2311-8571.351508","url":null,"abstract":"Transdermal drug delivery plays a significant part in the drug delivery system when compared to other routes of drug administration. The function of the stratum corneum (SC) is a barrier. Recently, numerous methods have been thrived to improve the perforation of drugs across the skin. The most effective method is to use enhancers since these agents enhance skin permeability. Natural penetration enhancers like essential oils demonstrate higher enhancement activity and are more widely accepted than synthetic penetration enhancers. High potential in the expansion and interaction with the SC intercellular lipids has led to an increasing interest in these oils as penetration enhancers. This article gives an overview of a few essential oils, including their mode of action and important parameters for permeation improvement. The present work can provide essential oils as alternative enhancers, and this could be useful in transdermal administration.","PeriodicalId":23692,"journal":{"name":"World Journal of Traditional Chinese Medicine","volume":"9 1","pages":"258 - 269"},"PeriodicalIF":4.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43940737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：